Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature review

Anaplastic lymphoma kinase (ALK) fusion is a well‐defined biomarker for ALK tyrosine kinase inhibitors (TKIs) treatment in non‐small cell lung cancer (NSCLC). Alectinib, a second‐generation ALK‐TKI, has been shown to have significantly longer progression‐free survival (PFS) than first‐generation ALK...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Mengnan, An, Zhou, Tang, Qiusu, Ma, Yutong, Yan, Junrong, Chen, Songan, Wang, Yina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500978/
https://www.ncbi.nlm.nih.gov/pubmed/34541785
http://dx.doi.org/10.1111/jcmm.16897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500978/
https://www.ncbi.nlm.nih.gov/pubmed/34541785
http://dx.doi.org/10.1111/jcmm.16897

Ejemplares similares